Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human embryonic stem cell-derived retinal progenitor cells
- Development stage
- Unknown
- Lead developer
- AIRM
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal
01
Overview
Human embryonic stem cell-derived retinal progenitor cells (hESC-RPCs) are a type of cell therapy product generated by differentiating human embryonic stem cells into precursor cells of the retina. These therapies are primarily being developed for the treatment of degenerative retinal diseases such as Stargardt macular dystrophy and age-related macular degeneration (AMD). The most common form in clinical trials is the transplantation of hESC-derived retinal pigment epithelial (RPE) cells via subretinal injection. The mechanism involves replacing or supporting dysfunctional or lost RPE or photoreceptor cells to restore or preserve visual function. Clinical studies have demonstrated that subretinal transplantation is generally safe and well-tolerated, with some patients experiencing stabilization or improvement in visual acuity[1][2][3][4]. Immunosuppression regimens are often used to prevent rejection.
- Other names
- hESC-derived retinal progenitor cellshESC-RPCshuman embryonic stem cell-derived retinal pigment epithelial cellshESC-RPE
Beyond the preview
Go deeper on human embryonic stem cell-derived retinal progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human embryonic stem cell-derived retinal progenitor cells.